Indications for SLYND:
Swallow whole. 1 tab daily for 28 days; repeat.
Pre-menarche: not applicable.
Renal impairment. Adrenal insufficiency. Presence or history of progestin sensitive cancers. Liver tumors (benign or malignant). Hepatic impairment. Undiagnosed abnormal uterine bleeding.
Hyperkalemia or risk thereof. History of thromboembolism. Discontinue if thromboembolic event, jaundice, or liver dysfunction occurs. Consider discontinuing if prolonged immobilization due to surgery or illness. Bone loss. Diabetes. Evaluate for other causes if irregular uterine bleeding or amenorrhea persists. History of depression; monitor and discontinue if serious depression recurs. Postpartum period. Pregnancy: discontinue if occurs.
Monitor serum K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, K+-supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, aprepitant, barbiturates, bosentan, carbamazepine, efavirenz, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, rifabutin, rufinamide, St. John's wort); use backup or alternative method of contraception.
Acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, libido decreased, breast tenderness, menstruation irregular; serious thromboembolic events, ectopic pregnancy.
Packs—1, 3, 6